Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018

November 1, 2018 4:30 PM EDT

Q3 2018 performance in line with guidanceRevises full year 2018 financial forecast to reflect anticipated strong full year organic business performance, expected at the higher end of the previous forecast, and impact of PaxVax and Adapt Pharma acquisitions

GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2018.

FINANCIAL HIGHLIGHTS

... More